GI Meds Flashcards
(48 cards)
1
Q
Antibiotic choices to treat H. Pylori
A
- Amoxicillin
- Clarithromycin
- Metronidazole
- Tetracycline
**must be used in some form of combo
2
Q
Bismuth for treatment of H. Pylori MoA
A
- disrupts cell wall
- inhibits urease activity
- likely creates protective later in stomach, bicarb/mucus secretion
- decreases stool liquidity
3
Q
1st choice drug class to treat ulcers
A
Histamine2 receptor antagonists –> suppress secretion of gastric acid
4
Q
Histamine 2 receptor antagonist drugs (H2RAs)
A
- Cimetidine
- Famotidine
- Nizatidine
5
Q
Cimetidine MoA
A
- blocks H2 receptors, decreasing volume of gastric juice and [H+ ion]; reversible process
- effective specifically against nocturnal acid secretion; suppresses basal acid secretion
- cross BBB –> CNS effects
6
Q
Cimetidine uses
A
- GERD
- gastric/duodenal ulcers
- Zollinger-Ellison syndrome
- aspiration pneumonitis
- heartburn
7
Q
Cimetidine AEs
A
Binds to androgen receptors producing blockade
- gynecomastia, reduced libido, impotence
- CNS: confusion, hallucinations, depression, or excitation
- IV hypotension and dysrhythmias
*CYP inhibitor
8
Q
opioids and antacids
A
- inhibitory property of antacids leads to better high in opiate use
- increasing stomach pH allows for better opiate absorption/longer high
9
Q
Famotidine & Nizatidine differences from Cimetidine
A
- more potent and fewer drug interactions than Cimetidine
- no effect on H1 receptors; absorbed w/ or w/o food
- less CNS effects, no androgen binding
- weak CYP inhibition
10
Q
Famotidine & COVID 19
A
- in adults with mild-mod covid-19, tx with high dose famotidine led to early resolution of symptoms and inflammation
11
Q
long term H2RA safety issues
A
- cognitive impairment –> linked to dementia
12
Q
Most effective class of drugs to suppress gastric acid secretion
A
- PPIs/proton pump inhibitors
*End in -prazole
13
Q
Proton pump inhibitor (PPIs) drugs
A
- Omeprazole
- Esomeprazole
- Lansoprazole
- Rabeprazole
- Pantoprazole
14
Q
Omeprazole moa
A
- prodrug converted to active form inside parietal cell
- causes irreversible inhibition of H+, K+, ATPase and lasts until new one is synthesized
- inhibits basal and stimulated acid release
15
Q
omeprazole uses
A
- ulcers
- GERD
- hypersecretory conditions
16
Q
omeprazole AEs
A
HA, diarrhea, N/V, long term risk of CA
17
Q
omeprazole d-d interactions
A
- affects absorption of atazanacir, ketoconazole, itraconazole due to increased gastric pH
18
Q
Long term PPI safety (endocrine/nutritional/Hip fx)
A
- Endo: elevated serum gastric levels
- Nutrition: can lower B12 absorption
- Hip Fx: higher dose = higher risk; presumed that cid inhibition interferes with Ca2+ absorption in small intestine
19
Q
Long term PPI safety (C. Diff, Plavix, CKD)
A
- CA-C. diff: theorized that decrease in gastric acidity may be “permissive” to enteric infection
- Plavix: omeprazole reduces efficacy; pantoprazole less likely to do so
- CKD: significantly higher incidence of CKD in PPI users
20
Q
Long term PPI safety (Cognition & pediatric use)
A
- Cognition: long term use linked to dementia
- Peds: use of lansoprazole in poorly controlled asthma showed no improvement; increased respiratory symptoms and community acquired pneumonia
21
Q
H. Pylori newest tx regimen (2)
A
- Quadruple therapy (PBMT)
–> PPI, Bismuth, Metronidazole & Tetracycline
OR - Concomitant therapy (PAMC)
—> PPI, Amoxicillin, Metronidazole, Clarithromycin
22
Q
Sucralfate use
A
- mucosal protective agent
- other ulcer tx drug
- binds to actual ulcer, MoA unknown
23
Q
Misoprostol moa/use/AEs
A
- prostaglandin analog
- other ulcer tx drug
- moa: inhibits acid and protects mucosal lining; short half life, freq. dosing needed
- use: NSAID induced ulcers
- AE: stimulates uterine contractions, abd pain, diarrhea (often using in L&D!)
24
Q
Antacids effects
A
- neutralize stomach acid; different capacities depending on the compound
- enhances mucosal protection by stimulating PG production, used for ulcers
- symptomatic relief, doesnt accelerate healing
25
Antacid types
- Al (aluminum related compounds)
- Mg (milk of magnesia)
- CaCO3 (Tums)
- NaHCO3 (Baking soda, alka seltzer)
26
Antacid combo examples
- Maalox --> Al3+ & Mg2+
- Mylanta --> CaCO3 & Mg(OH)2
27
Anticholinergics for ulcer disease effects AEs
- Pirenzepine
- produces selective blockage of M receptors that regulate gastric secretion
- AEs: dry mouth, constipation, N/V/D
28
Laxative types (6)
- Bulk
- Surfactant
- Lubricant
- Osmotic
- Stimulant
- Serotonin Receptor agonist
29
Bulk laxatives effects/AEs
ex. Metamucil
- increases volume/stretches intestinal wall stimulating peristalsis
- used in IBS, diverticulosis, diarrhea
- **AEs: esophageal obstruction if not taken with water
30
Surfactant laxative effect
ex. Docusate/Colace
- lowers surface tension of stool, facilitates water penetration; inhibits fluid absorption & stimulates secretion of water/electrolytes into intestine
31
Lubricant laxative ex.s
- glycerin suppository & mineral oil
32
Osmotic laxative effect
ex. Milk of magnesia, Sorbitol, Lactulose
- increases liquidity of stool due to increase stool fluid
33
stimulant laxatives effects
ex. Bisacodyl/Dulcolax, Senna, Castor oil
- acts on small intestine/colon to produce soft/semi fluid stool
34
Serotonin receptor agonist laxatives effects and AEs
ex. Tegaserod
- 5HT4 partial agonist --> stimulates peristalsis, increases stool liquidity
- AEs: diarrhea, resolves alone
- restricted use for IBS
35
Anti-diarrheal agents (3)
- opioids
- loperamide
- Diphenoxylate
36
tri-cyclic anti-depressants in IBS moa
- alter central processing of visceral afferent info
- anticholinergic effects leads to motility and secretion
- decreases nociception
37
Serotonin 5HT3 receptor agonist in IBS moa/AEs
- drug: Alosteron
- blocks receptors in gut on way to spinal cord inhibiting sensation of N, pain and bloating-slowsclonic transit
- AEs: constipation requiring hospitalizations, ischemic colitis
38
antispasmodics (anticholinergics) in IBS moa
- Dicyclomine, Hyoscyamine
- inhibits muscarinic cholinergic receptors in the enteric plexus/on smooth muscle
- low doses, minimal ANS effects; high doses = dry mouth, visual disturbances, urinary retention
39
Probiotics
- dietary supplements thought to inhibit bacterial toxins, lower pH, and inhibit growth of pathogenic bacteria; physically/chemically prevent adhesion and colonization of pathogenic bact.
40
Probiotics AEs
- gas, bloating, diarrhea, eructations
- usually mild/transient
- infectious complications have occurred in highly immunosuppressed/critically ill pts
41
sulfasalazine use/Aes
- 5-aminosalicylate used for Crohns/UC
- suppresses prostaglandin synthesis and migration of inflammatory cells into area
- AEs: N, fever, rash, arthralgia, hematologic disorders
42
Anti-Emetics: 5HT3 receptor blocker
ex. Ondansetron
SE: HA, diarrhea, dizziness
- useful for chemo tx induced and post op N/V
43
Anti-Emetics: Substance P/Neurokinin antagonist
ex. Aprepitant
- prevents acute & delayed N/V
- inhibitor and inducer of CYP3A4
44
Anti-Emetics: Prokinetic agents
ex. Metoclopramide
- suppresses emesis by blocking 5HT & DA; increases upper GI motility by enhancing actions of ACh
- uses: GERD, DM gastroparesis, N/V r/t chemo or post-op
- SEs: EPS, BBW--> tardive dyskinesia, sedation
45
Anti-Emetics: muscarinic antagonist
*most useful for motion sickness
- block M and H1
- SE: sedation, dry mouth, blurred vision
46
Anti-Emetics: benzodiazepines
- suppresses anticipatory vomiting in chemo
47
Anti-Emetics: glucocorticoids
- moa unknown
48
Anti-Emetics: phenothiazines
- D2 blocker
SE: EPS, anticholinergic effects, hypotension, sedation
